News and Trends 6 Dec 2022 New brain tumor subtypes discovery may help develop treatments for incurable brain cancer Research led by RCSI University of Medicine and Health Sciences in Ireland has discovered three new subtypes of brain tumor. This could help to identify new and effective therapies. The novel tumor subtypes are forms of glioblastoma, the most common and most aggressive form of adult primary brain cancer with no cure currently available. The […] December 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 ImaginAb launching clinical trial for renal cancer and malignant melanoma ImaginAb Inc., which is focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapy (RPT) products, is starting a phase II clinical trial. The trial, PRETZCEL, which will take place at Hull University Teaching Hospitals NHS Trust in the U.K., will investigate ImaginAb’s investigational CD8 ImmunoPET agent in patients with melanoma or […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Startup Graegis developing therapies for radiation side-effects Graegis Pharmaceuticals, a startup developing new therapies aimed at preventing the side effects of radiotherapies, is set to complete the regulatory nonclinical package allowing entry in clinical trials. The company, founded in the last quarter of 2021, spent the first year of operations running critical experiments on the new therapies, which will target radiation side […] December 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 New company Liminatus Pharma Inc to develop three cancer treatments Clinical-stage biopharma company Liminatus Pharma LLC and Iris Acquisition Corp, a publicly traded special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed Liminatus Pharma, Inc.. The […] December 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Singapore researchers develop affordable cancer testing method Scientists from the National University of Singapore (NUS) have discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, the new test sequences clinical samples that have been heated in order to isolate cancer-specific signatures found in a patient’s blood. The new method provides a promising non-invasive alternative to tissue biopsies. It […] December 5, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 Faron Pharmaceuticals provides cancer treatment update Faron Pharmaceuticals Oy has given an update on its phase I/II BEXMAB study, investigating bexmarilimab. Bexmarilimab is Faron’s wholly owned precision immunotherapy asset, in combination with standard of care (SoC) in multiple hematological malignancies. The Finnish company said an azacytidine-refractory acute myeloid leukemia (AML) patient with partial responses as communicated on October 31, 2022, achieved […] December 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2022 Partnership to deliver oncology workflow for 7 European hospitals A BC Platforms (BCP) partnership that includes Finland’s Euformatics and Hungary’s Oncompass Medicine has been awarded a contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven European hospitals, represented by the Medical University Graz. The consortium is formed by hospitals from the Medical University of Graz in Austria, […] December 2, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2022 Full-Life Technologies acquiring Focus-X Therapeutics Full-Life Technologies, a global radiotherapeutics company, is acquiring New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on peptide engineering technology. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its radiotechnology manufacturing and logistics platforms to advance compounds […] December 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2022 Trial for HPV16 positive oropharyngeal cancer completes enrolment for phase 2 Netherlands-based ISA Pharmaceuticals B.V., has announced that it has completed enrolment in its phase 2 clinical trial. Named OpcemISA. The trial aims to checkpoint inhibitor therapy in patients with metastatic/advanced 1st and 2nd line HPV16 positive oropharyngeal cancer (OPC). The clinical stage biotech company is developing immunotherapies to treat cancers and infectious diseases, and has […] December 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 SOTIO exercises option on ADC program SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies of solid tumor indications. In November 2021, SOTIO and LCB entered into a multi-target exclusive collaboration and license […] November 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 AstraZeneca splashes out up to $320M on T-cell receptor therapy company Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), has entered into a definitive agreement to be acquired by Astrazeneca. AstraZeneca will acquire all outstanding equity of Neogene Therapeutics for a total consideration of up to $320 million, on a cash and debt free […] November 30, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 29 Nov 2022 LAG-3: The next big checkpoint inhibitor target Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of […] November 29, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email